ALNY— AI Stock Forecast & Price Targets
Published 8/12/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live ALNY price forecast →
ALNY was violently repriced from ~$360 to $217 following the July 30 Q2 print and $200M TTR guidance cut, with the tape now sitting 11% above the 52-week low and 55% below the highs. Fundamentals remain genuinely strong (Q2 revenue $1.29B, FCF $292M, forward P/E ~17.2, PEG 0.29, 95% YoY sales growth) but management credibility has been damaged and ATTR-CM uptake sustainability is now the central question. This is an accumulation setup for patient capital, not a rip-your-face-off bounce trade — the base needs to build before the tape re-rates.
1-4 weeks: Small starter position only, or wait for confirmation. Price is basing at $210-$225 just above the $197.81 52-week low but there's no evidence of accumulation yet — RSI 35.9 is oversold-neutral, not washout. The forecast model's daily bullish signal is unreliable here (beaten by naive baseline). Preferred approach: buy 1/3 of intended size at current $217, add 1/3 on a confirmed reclaim of $235 (SMA20 area) with volume, hold last third for either a break above $250 (thesis validation) or a flush to $190-$197 (better entry). Hard invalidation: daily close below $195 — that opens $170-$180 and forces a re-underwrite. No earnings catalyst until Oct 29.
1-6 months: The setup rewards patience. Base case is that ATTR-CM demand stabilizes at the revised run-rate, Q3 print (Oct 29) confirms no further cuts, and the stock re-rates to $250-$260 as forward P/E of 17x expands modestly. Bull case requires either a positive pipeline catalyst (ALN-6400 Phase 1 H2 2026, zilebesiran readouts) or evidence of ATTR-CM re-acceleration — that could carry the stock to $280-$310. Bear case is a second guide cut on the Q3 print, which would break $197 and target $170-$180. Expected return range from $217: -20% to +35% with the base near +15%. What changes my mind: any 8-K signaling further TTR weakness, or competitive share loss data on acoramidis.
1-3 years: The terminal thesis rests on ATTR-CM (10-50x larger TAM than polyneuropathy) plus pipeline optionality across zilebesiran (hypertension with Roche), nucresiran, cemdisiran, and elebsiran. If Alnylam holds even 30-40% share of the ATTR-CM market with Amvuttra and gets one non-TTR Phase 3 to approval, revenue could reach $7-9B by 2029-2030 with meaningful FCF. That supports a $350-$500 price target on a normalized 5-6x sales / 25x FCF basis. Biggest structural risk: RNAi platform economics get compressed by competing modalities (next-gen orals, gene editing, small molecules like acoramidis) and single-franchise concentration means one clinical setback could reset the whole valuation. Aggressive Inceptive AI spending is a wildcard — could compound optionality or destroy capital.
The business itself remains genuinely strong despite the tape carnage. Q2 2026 revenue of $1.291B (+66.9% Q/Q sales growth, 95.1% Y/Y TTM per the fundamental-change signal) was a record, gross margin held at 76.9%, operating margin 17.9%, and free cash flow surged to $292M from $49M the prior quarter — cash flow durability is real. TTM EPS of $5.75 puts trailing P/E at 37.7 but forward P/E is only 17.2 with PEG 0.29, implying the market is pricing in materially lower forward growth than consensus. Balance sheet is solid: $1.71B cash, $1.27B debt, current ratio 3.05, working capital $3.1B. ROE of 100.7% and ROIC of 20% are elite. What's broken: management credibility took a hit with the $200M TTR guide cut ($4.4-4.7B → $4.2-4.5B), and the admission that early Amvuttra strength was partly one-time backlog demand raises real questions about sustainable run-rate. The $2B Inceptive AI commitment plus continued R&D intensity means margin expansion is not assured. Overall this is a high-quality biotech getting re-rated on trajectory rather than absolute fundamentals — the numbers support ownership, but the story has been damaged.
The tape is decisively broken. The 1h chart shows a violent gap from ~$300 to ~$215 on the July 30 print, and the stock has spent nearly two weeks basing in a tight $210-$225 range just above the 52-week low of $197.81. On the daily, the multi-month uptrend from $275 support has been shattered — price sits 55% below the $495.55 52-week high, 35% below the SMA200, 20% below SMA50, and 11% below SMA20. RSI at 35.9 is oversold but not deeply so, suggesting the selling may not be finished. The weekly chart shows the entire 2025 rally has been unwound. Notably, the forecast model has been beaten by naive baseline on daily horizons (30% vs 71% directional accuracy, 38% MAPE) — its bullish signal here should be heavily discounted. The 4h and daily forecast bands do project $347-$370 recovery, but past bull targets on this name have systematically run 40-120% high, so those should be treated with skepticism. Key levels: $197.81 (52-week low) is the make-or-break support; a break there opens $170-$180. Upside resistance sits at $250 (prior consolidation), then $273 (former pivot), then $300 (gap fill). No confirmed base yet — just a shelf being tested.
The dominant signal is the July 30 Q2 print (8-K Item 2.02) which triggered a 24-30% single-day selloff on the $200M TTR guidance cut and management's acknowledgment that early Amvuttra strength included one-time backlog demand. This was institutional-driven selling, not retail panic, which typically indicates informed reassessment. Sell-side has been cutting: Truist slashed target from $410 to $315 (still Buy), HC Wainwright from $485 to $455 (still Buy), and the fundamental-change signal shows consensus PT dropped from $426.52 to $401.70. Consensus rating remains constructive at 1.60 (near strong-buy) with a $379 target implying ~71% upside, but analysts have been consistently too optimistic on this name. Implied volatility surged post-earnings per Zacks/Yahoo coverage. Signal vs noise: the guidance cut is real and material; the $1000-invested-20-years-ago style pieces are noise. Retail sentiment on stocktwits is 100% bullish among tagged messages — a classic contrarian caution flag when combined with a broken tape.
- Amvuttra ATTR-CM label expansion: 10-50x larger TAM than the original polyneuropathy indication; sustained penetration would drive revenue toward $6B+ by 2028
- Zilebesiran (hypertension, partnered with Roche): potential first RNAi drug in a massive cardiovascular market — Phase 3 readouts are a multi-year catalyst
- Nucresiran (Phase 3, ATTR amyloidosis): next-gen TTR asset that could extend the franchise and defend against competitors like acoramidis
- ALN-6400 (Phase 1, bleeding disorders): H2 2026 readout is a near-term pipeline validation point per the internal watch list
- Cemdisiran (Phase 3 across myasthenia gravis, PNH, geographic atrophy) and elebsiran (Phase 3, hepatitis D) diversify beyond TTR
- Cash generation inflection: FCF jumped from $49M in Q1 to $292M in Q2 — sustained conversion could self-fund pipeline without dilution
- Further TTR guidance cuts on the Oct 29 Q3 print — management credibility already damaged by the $200M cut
- ATTR-CM patient backlog normalization masks true underlying demand curve; real run-rate may be lower than modeled
- Competitive share loss to acoramidis (BridgeBio) in second-line ATTR-CM, plus next-gen entrants
- Technical break below $197.81 52-week low opens path to $170-$180 based on prior support shelves
- $2B Inceptive AI commitment plus elevated R&D compress margin expansion if revenue growth slows
- Single-franchise concentration — TTR still dominates revenue, so any franchise disruption is disproportionately punishing
- Sell-side targets have systematically run 40-100%+ above realized price on this name; consensus $379 target may be a mirage
- Model forecast reliability is poor at daily horizon (30% vs 71% naive baseline) — the bullish signal is unreliable in this regime
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord